Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 10/20 | 0.44 |
| ▸ | NT5E | P21589 | 5/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370337 | 0.92 | CDK2 (0.45) | CDK2MAPK1MAPK8CSNK1A1CSNK1D | |
| SCHEMBL22843534 | 0.89 | CDK2 (0.48) | CDK2MAPK1MAPK8CSNK1A1CSNK1D | |
| SCHEMBL21450235 | 0.87 | NT5E (0.54) | CDK2CDK1NT5ECCNB2CCNB1 | |
| SCHEMBL24078872 | 0.86 | P2RY1 (0.42) | CDK2MAPK1MAPK8CSNK1A1CSNK1D | |
| SCHEMBL19370287 | 0.86 | CCNB2 (0.47) | CDK2CDK1NT5ECCNB2CCNB1 | |
| SCHEMBL19370351 | 0.84 | NT5E (0.50) | CDK2CDK1NT5ECCNB2CCNB1 | |
| SCHEMBL22843550 | 0.81 | CDK2 (0.46) | CDK2MAPK1MAPK8CSNK1A1CSNK1D | |
| SCHEMBL22843662 | 0.77 | ADORA3 (0.41) | CDK2MAPK1MAPK8CSNK1A1CSNK1D | |
| SCHEMBL19370191 | 0.76 | NT5E (0.57) | CDK2CDK1NT5E | |
| SCHEMBL22214990 | 0.76 | CDK1 (0.55) | CDK2MAPK1MAPK8CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981944-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | CDK2 4092/4885MAPK1 4187/4885MAPK8 3664/4885 |
| US-10981944-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | CDK2 4053/4885MAPK1 4163/4885MAPK8 3635/4885 |
| US-20190309010-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | CDK2 4092/4885MAPK1 4187/4885MAPK8 3664/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | CDK2 4053/4885MAPK1 4163/4885MAPK8 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.